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Medical Treatment of Hyperprolactinemia Associated with Pituitary Tumor 
K. v. Werder, R. Fahlbusch, R. Landgraf, C R . Pickardt, H.K. Rjosk and P.C. Scriba, 
Munich, FRG 
Summary 
Forty-five female patients with prolactin-producing tumors (hPRL: 2000 to 80000juU/ 
ml) and 22 male patients (hPRL: 16000 to 400000/iU/ml) were studied. Only 25% 
of the females had visual field defects which were present in 70% of the males. All 
females had amenorrhea whereas only 31 had galactorrhea. Hypopituitarism was rarely 
seen in the females but was observed in most of the male patients. Twenty females and 
all male patients were operated upon (transsphenoidal or transfrontal hypophysectomy). 
Normalization of hPRL levels was achieved in only four females and in none of the 
males. One patient became pregnant postoperatively, four further patients after post-
operative treatment with bromocriptine. Bromocriptine induced regular periods in 4 
further patients operated upon by the transsphenoidal route. Eight patients with micro-
adenomas (hPRL<4000 / iU /ml ) were treated with bromocriptine alone; two of these 
became pregnant. The males were also treated with bromocriptine which led to a 
significant fall of the hPRL level accompanied by improvement of libido, sexual pot-
ency and headaches. Two patients received radiation postoperatively, which also led 
to a fall of hPRL levels and improvement of visual field defects. Since hPRL levels 
remained low for several months after discontinuation of bromocriptine an anti-
proliferative effect of this drug is suggested. Thus differential therapy for PRL-produc-
ing tumors is possible: in females selective neurosurgery alone or combined with medi-
cal therapy may normalize hPRL secretion and ovarian function. In patients with a 
microadenoma bromocriptine alone may be successful. In patients with inoperable 
large tumors radiation should be advocated. Additional bromocriptine therapy is 
necessary to stop tumor growth and alleviate the effects of hyperprolactin-
emia. 
Introduction 
Since the radioimmunoassay for human prolactin (hPRL) has become available [ 1 , 2 ] 
a large number of paitents with elevated prolactin levels have been discovered. Particu-
larly in females hyperprolactinemia with and without pituitary tumors has been shown 
to be a frequent cause of galactorrhea, amenorrhea or anovulatory menstrual cycles 
[ 3 , 4 ] . But also in the male where galactorrhea is usually absent, it could be shown 
that many pituitary tumors formerly thought to be hormonally inactive were in fact 
producing prolactin [3 , 5] . It seems as if the pituitary prolactinoma is the most fre-
quent of all endocrinologically active pituitary tumors [ 6 , 7 ] . In the last three years 
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we have been observing more than 100 patients with hyperprolactinemia in our endo-
crine clinic, who were treated either by surgical procedures [6], by conventional radia-
tion, with bromocriptine, or by a combination of these therapeutic regimes [7]. 
Methods 
Human prolactin was measured by radioimmunoassay using the VLS-hPRL for labeling, 
kindly donated by the National Institute of Health. Pooled pregnancy serum served as 
standard; this was calibrated with the MRC-Research-Standard A-71/222 [8], kindly 
supplied by the National Institute for Medical Research, Holly Hill, London. 20juU 
of the MRC-Standard A-71/222 are equivalent ot 1 ng VLS-hPRL from the NIH. A 
rabbit antiserum raised against the "l i t t le" fragment of serum hPRL served as hPRL 
antibody, as described previously [9] . The bound/free separation was performed by 
the double-antibody-procedure. No cross-reactivity with other pituitary hormones or 
lactogenic hormones was observed in our radioimmunoassay; the lower limit of detec-
tion was 5juU/ml. 
Hormone determinations: human growth hormone (hGH), luteinizing hormone (LH), 
follicle-stimulating hormone (FSH) and thyrotropin (TSH) were measured by standard-
double-antibody-radioimmunoassay [3] . Serum Cortisol was also measured by radio-
immunoassay, thyroxin by competitive protein-binding analysis. 
Pituitary function was evaluated with the following stimulation tests: 
Thyrotropin-releasing hormone (200fig TRH) for the stimulation of TSH and 
hPRL 
Gonadotropin-releasing hormone (25 jug GnRH) for the stimulation of LH and 
FSH. 
Insulin hypoglycemia (0.15 U/kg body weight) for the stimulation of Cortisol and 
hGH. 
Anatomical evaluation in order to demonstrate a pituitary tumor: In all patients lateral 
skull x-rays as well as sella tomography were performed. Most of the patients had a 
computer tomography (CT) of the skull done on them. In all patients visual fields were 
examined. 
Patients 
The patients investigated were referred to us because of amenorrhea and galactorrhea 
because of clinical evidence of pituitary insufficiency or because of visual field prob-
lems. All patients (45 females and 22 males) were admitted to the hospital before the 
initiation of surgical or medical therapy in order to perform the endocrine evaluation. 
If the patients were operated upon, pituitary function tests were repeated 6 weeks 
postoperatively. 
Results and Discussion 
Prolactin levels in 45 female patients with amenorrhea and generally galactorrhea and 
pituitary tumors ranged from 1100 to 80000/iU/ml (Fig. 1). As has been shown 
previously [6] , there was a good correlation between tumor size and the amount of 
circulating prolactin. Thus the prolactin levels in females with amenorrhea, galactorrhea 
and normal sella did not exceed 3500juU/ml (Fig. 1). Only 15% of the females with 
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pituitary tumors had visual field defects whereas 70% of the male patients had supra-
sellar extension of the tumor as documented by CT and visual field defects. Of these 
22 male patients only 7 were investigated before the first operation (Fig. 1), though 
all had prolactin levels above 6 OOOjuU/ml ranging up to 400000/xU/ml in one patient 
after several transfrontal and transsphenoidal pituitary operations; this again gives 
evidence for the strong correlation between tumor size and prolactin concentration. 
Hypopituitarism, as demonstrated by insufficient responses of pituitary hormone 
secretion after appropriate stimulation, was rarely seen in the females whereas most 
of the male paitents showed lack of growth hormone and gonadotropin secrerion. 
All patients with pituitary tumors and signs of pituitary insufficiency and/or evidence 
of suprasellar extension were operated upon by the transsphenoidal and sometimes 
transcranial route [6]. As pointed out previously [6, 10] it is extremely difficult to 
cure the prolactin excess by surgical means if prolactin levels are very high (Fig. 2) . 
Thus out of 20 females with elevated prolactin levels normalization was achieved only 
in 6, one of whom became pregnant, whereas prolactin levels remained elevated in the 
other 14 patients (Fig. 2). In the male patients with the higher prolactin levels no 
normalization could be observed after transsphenoidal hypophysectomy, though there 
was a significant fall of basal prolactin levels in all of them (Fig. 2). 
A typical example of a female patient with galactorrhea, amenorrhea, a pituitary tumor 
and chiasma syndrome is shown in Fig. 3 . In this patient, who showed already impaired 
anterior pituitary function preoperatively together with suprasellar extension of a 
large prolactin-producing adenoma, operation was performed by the transsphenoidal 
route in addition with cryotherapy. Immediately after the operation the prolactin level 
levels were normalized and visual field restored to normal whereas the patient now 
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preop. postop. preop. postop. 
hPRL 
Fig. 3 Intra- and postoperative P R L levels in a patient with a large prolactinoma 
showed complete anterior pituitary failure and required substitutional therypy. Though 
in this case a radical ablation of the pituitary had been intended and was performed, 
a gradual increase of prolactin levels has been observed during recent follow-up inves-
tigations , suggesting a recurrence of pituitary tumor growth [11]. 
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Since it has been shown that prolactin levels can be effectively lowered by dopamine 
agonists [12, 13, 1 4 , 1 5 ] , we have treated 19 female patients with pituitary tumors 
with bromocriptine, which was well tolerated by all of the patients. Bromocriptine in 
daily dosages varying from 3 to 7.5 mg normalized prolactin levels in female patients 
with pituitary tumors, if the postoperative basal prolactin level did not exceed 
10000juU/ml (Fig. 4) . Four of these patients became pregnant after bromocriptine ad-
ministration and had a completely normal pregnancy, delivering healthy babies. In the 
females with prolactin levels above 10000/xU/ml even larger doses of up to 30 and 40mg 
daily did not lead to normalization of prolactin secretion and subsequent cyclic ovarian 
function. 
A typical example of a patient with a prolactinoma, prolactin levels above 12000/iU/ml, 
visual field defects and partial pituitary insufficiency documented by inadequate re-
sponses of hGH, LH and TSH, is given in Fig. 5. Since this paitent wanted to become 
pregnant, in contrast to the patient shown in Fig. 3 , a selective adenomectomy was 
performed, so that after the operation pituitary function could recover or remain in-
tact. Due to residual adenomatous tissue, the basal prolactin levels after operation 
fluctuated between 4000 and 7000juU/ml. The patient was therefore treated with 
7.5 mg bromocriptine per day. After the first menstrual period she become pregnant 
and delivered a normal child. After an almost normal breast-feeding period she was 
again treated with bromocriptine and became pregnant again, giving birth to a second 
child in February 1977. 
hPRL 
[pU/ml] 
month of t reatment 
Fig. 4 Effect of long-term treatment with bromocriptine in 19 female patients with prolactinomas 
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Fig. 5 Pregnancy after partial adenomectomy in a patient with a prolactinoma. Normal hPRL 
levels were obtained only after therapy with bromocriptine 
A similar case is shown in Fig. 6. After surgical resection of the pituitary adenoma 
without destroying residual pituitary function, the still elevated prolactin levels could 
be completely normalized by bromocriptine administration, leading to disappearance 
of the galactorrhea and normal menstrual cycles. After discontinuing the administra-
tion of bromocriptine, which had been given only for a short period, prolactin levels 
increased again to the initial values and galactorrhea and amenorrhea recom-
menced. 
In cases where prolactin levels were only moderately elevated, in patients who wanted 
to become pregnant and the pituitary tumor was small without any evidence of pitui-
tary dysfunction or suprasellar extension, we treated these patients with bromocriptine 
alone. Fig. 7 shows the course of treatment in a patient with an asymmetrically grow-
ing pituitary tumor without visual field defects and no evidence of anterior pituitary 
dysfunction. Prolactin levels were 3000juU/ml. After therapy with 3mg bromocriptine 
per day the prolactin levels had normalized and she ovulated regularly. She became 
pregnant and treatment with bromocriptine was stopped after which the prolactin 
levels rose again during pregnancy up 18000/iU/ml. The patient delivered a normal 
child and since her prolactin levels did not fall to pretreatment levels and she suffered 
from heavy galactorrhea she was then operated upon by the transsphenoidal route. 
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Fig. 7 Pregnancy after bromocriptine therapy alone in a prolactinoma patient. Since hPRL levels 
remained elevated compared to pretreatment levels she was operated upon after delivery before 
bromocriptine was started again 
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The operation was again not a radical one, because a second pregnancy was desired 
Therefore her prolactin levels did not drop to normal again necessitating bromocriptine 
therapy which led to regular menses. 
There are two reasons why the indication for bromocriptine therapy is not confined to 
females: the first reason for trying to normalize prolactin levels in male patients is that, 
in contrast to former beliefs, hyperprolactinemia exerts biological effects also in the 
male [3 , 5 , 1 2 , 16]. Thus it is a well established clinical finding that male patients with 
high prolactin levels suffer from lack of libido in the presence of normal testosterone 
secretion or, respectively, adequate testosterone substitutional therapy [3 , 5] . Si ice 
prolactin has a diabetogenic effect, a deterioration of the glucose tolerance may also 
be observed [16]. 
We treated 14 male patients who all had elevated prolactin levels postoperatively and 
complained of headaches, depression and, particularly, loss of libido and impotence in 
the presence of adequate testosterone substitution with bromocriptine (Fig. 8). In 7 
patients the prolactin levels were normalized by bromocriptine whereas they remained 
elevated, though considerably lowered, in the other 7 patients. The fall in prolactin 
levels was in general accompanied by clinical improvement and a feeling of well-being. 
In contrast to the findings in females, prolactin levels above lOOOOjuU/ml in males 
could be normalized by bromocriptine; this may be due to the lack of estro-
gens with their permissive action on prolactin secretion [17]. This is also demonstrated 
by a male patient who had been operated upon by the transsphenoidal route because 
of a pituitary prolactinoma which was previously thought to be hormonally inactive 
(Fig. 9). Postoperatively he still showed prolactin levels of more than 12000juU/ml. 
He suffered from lack of libido and sexual impotence though there was no evidence 
of pituitary dysfunction and peripheral testosterone levels were in the normal range. 
He was treated with bromocriptine and on the relatively small dose of 3mg per day pro-
lactin secretion normalized and sexual potency as well as libido and fertility returned 
to normal (Fig. 9). 
hPRL-71/222 
pU/ml 0p°£i 
400000( 
preop postop 1 2 3 U 5 6 7 8 9 10 11 12 13 U 15 16 17 
M o n t h of t r e a t m e n t 
Fig. 8 Effect of long-term treatment with bromocriptine in 14 male patients after operation of 
a prolactinoma 
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Fig. 9 Postoperative treatment with bromocriptine in a patient with remaining hyperprolactinemia 
and disturbance of libido and sexual potency 
The other reason for treatment with bromocriptine in males and females with prolactin-
omas and postoperatively persisting hyperprolactinemia is evidence accumulated re-
cently that this drug has an antiproliferative effect on lactotrophic pituitary tumor 
growth [18, 19]. 
Four patients with pituitary tumors and elevated prolactin levels were treated for 5 to 
20 months with bromocriptine in dosages ranging from 5 to 40mg per day (Table 1). 
Table 1 P R L Levels (/iU/ml) in 4 Female Patients with Pituitary Tumors after Discontinuation 
of Long-term Treatment with Bromocriptine 
Patient hPRL before hPRL after Duration of Dosage of Time period with-
therapy discontinuation treatment bromocriptine out bromocriptine 
of therapy (months) (mg/day) (months) 
A . L . 49340 12982 12 12.5 1 
J.H. 41910 15655 5 40 8 
S.L. 16680 10578 13 40 11 
G.G. 5237 3100 20 5 2 
Bromocriptine therapy was then stopped for a period of 1 to 11 months, after which 
the prolactin levels were still found to be significantly lower than pretreatment levels, 
suggesting the antiproliferative effect mentioned above. Further evidence has been 
provided by a male patient with excessive hyperprolactinemia after two transfrontal 
and two transsphenoidal operations (Fig. 10). His prolactin levels were extremely 
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Fig. 10 Improvement of visual fields defects, headaches, lack of libido and sexual impotence in 
a patient with a prolactinoma after administration of bromocriptine 
elevated - 400000juU/ml, which is equivalent to 20jug of hormone protein per ml. 
This patient who is now suffering from complete panhypopituitarism due to his in-
vasively growing and inoperable prolactin-producing tumor, complained mainly of 
headaches, depressions, lack of libido and sexual impotence. He also had impaired 
visual fields. Under chronic bromocriptine therapy he feels subjectively better and the 
prolactin levels have fallen from 400000 to less than 5000juU/ml. There is no evidence 
for progression of tumor growth; on the contraiy, the perimetry demonstrates im-
provement of his visual field which suggests actual shrinking of the pituitary tumor 
(Fig. 10). 
That prolactin levels correlate to tumor size has been mentioned before [6]. That pro-
lactin levels correlate in individual patients also with tumor growth is documented by 
a patient with galactorrhea, amenorrhea and a pituitary tumor who was operated upon 
by the transfrontal and the transsphenoidal route because of impairment of visual 
fields (Fig. 11). When, after two operations, this patient was first admitted to our 
hospital the prolactin levels were still elevated. During follow-up examinations, deteri-
oration of visual fields was observed due to tumor growth, accompanied by a sharp 
rise of basal prolactin. The patient was inoperable because of severe congestive heart 
failure and therefore received radiation therapy after which the prolactin levels fell 
and a slight improvement of her visual field was noted. She was then put on bromo-
criptine which led to a prompt normalization of prolactin secretion; her visual fields 
have remained improved. 
Bromocriptine has been shown to inhibit growth-hormone secretion in patients with 
acromegaly [20, 2 1 , 22, 23] . That bromocriptine may be helpful in patients with hyper-
secretion of hGH and hPRL has been demonstrated in the case illustrated in Fig 12. 
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Fig. 11 Correlation of prolactin levels and pituitary tumor growth as evidenced by increasing 
visual field defects 
This history of this unfortunate acromegalic lady demonstrates quite clearly the prob-
lems we sometimes face on managing patients with endocrine-active pituitary tumors. 
She was first operated on in 1969 by the transfrontal route in an outside institution. 
Preoperative growth-hormone and prolactin levels were not knwon. The indication for 
operation was the clinical picture of acromegaly. Because of suprasellar extension of 
the pituitary tumor leading to visual field disturbances she was operated on again by 
transfrontal approach; this operation did not lower her growth-hormone levels at all, 
though in 1974 when she appeared for follow-up examination her growth-hormone 
level was 20ng/ml and her prolactin level lOOOOjuU/ml, demonstrating that she suffered 
from hypersecretion of both hGH and hPRL. Because of rapid deterioration of the 
visual function of her left eye, she came to our hospital again and was operated on a 
third time, this time by the transsphenoidal route. Again there was no significant effect 
on growth-hormone and prolactin levels which were still very high. By computer tomo-
graphy it could be demonstrated that she there was pre- and suprasellar tumor growth 
leading to complete blindness of her left eye. Therefore we put her on bromocriptine 
therapy which effectively lowered growth-hormone levels and even more effectively 
prolactin levels. We regarded this as particularly important since in the meantime 
breast cancer had developed in this patient which had to be treated surgically. The 
connection between the occurrence of breast cancer and hypersecretion of two lacto-
trophic hormones is still an object of speculation [24]. In this case we think that , in 
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Fig. 12 Effect of multiple surgical interventions and bromocriptine treatment on hPRL and hGH 
levels in a patient with acromegaly and hyperprolactinemia 
addition to bromocriptine therapy, radiation of the tumor will be necessary when she 
has recovered from the mastectomy. 
That bromocriptine can inhibit two hormones secreted by pituitary tumor has also 
been shown in a case recently reported by Horn et al. [25], where treatment with 
bromocriptine led to lowering of TSH and prolactin levels in a patient with a TSH- and 
prolactin-producing pituitary tumor. 
Final Conclusions 
From the findins in our 45 female and 22 male patients with pituitary tumors we can 
draw the following conclusions: 
1. Hyperprolactinemia associated with pituitary tumor can be treated surgically, 
medically and by radiation. 
2. All patients with visual field defects or signs of impairment of pituitary function 
should be operated. If operation is impossible, pituitary radiation is an alternative. If 
prolactin levels are not normalized after operation or radiation, particularly in 
cases where these patients suffer from depression, lack of libido or impotence despite 
adequate testosterone levels, t reatment withbromocript ine is indicated. 
3. In females with prolactin levels above 5000juU/ml who want to become pregnant, 
a gentle neurosurgical procedure should induce normalization or lowering of pro-
lactin secretion without disturbing gonadotropic function, so that postoperative 
bromocriptine therapy can lead to normal ovulatory cycles. 
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4. In patients with small pituitary tumors and hyperprolactinemia who do not show 
any evidence of pituitary insufficiency or visual field defects, treatment by bromo-
criptine alone is indicated. In case of pregnancy these patients have to be monitored 
very carefully since the enhanced estrogen production during pregnancy can activate 
pituitary tumor growth. 
5. Patients with endocrine-active pituitary adenomas secreting two different hormones 
seem to be responsive to bromocriptine therapy which leads to the abolition of 
both hormone excesses. 
6. There is good evidence that bromocriptine exerts an antiproliferative effect on pi-
tuitary tumor growth. It remains to be seen whether consistent postoperative treat-
ment with bromocriptine can prevent recurrence of pituitary tumor growth in every 
patient. 
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